Concord Biotech Ltd Faces Technical Momentum Shift Amid Bearish Indicators

Price Momentum and Recent Market Performance

Concord Biotech’s current market price stands at ₹1,150.00, down 1.41% from the previous close of ₹1,166.45. The stock traded within a range of ₹1,142.00 to ₹1,173.55 today, remaining close to its 52-week low of ₹1,100.00, and significantly below its 52-week high of ₹2,149.90. This wide gap underscores the steep decline the stock has experienced over the past year.

Examining returns relative to the benchmark Sensex reveals a stark underperformance. Over the past week, Concord Biotech declined by 10.4%, compared to a modest 0.98% drop in the Sensex. The one-month return shows a 14.66% fall against a near-flat Sensex movement of -0.14%. Year-to-date, the stock is down 14.53%, while the Sensex has declined by 2.08%. Over the last year, the divergence is even more pronounced, with Concord Biotech falling 31.22% while the Sensex gained 9.81%. These figures highlight the stock’s persistent weakness amid broader market resilience.

Technical Indicator Analysis: A Mixed Picture

The technical landscape for Concord Biotech is nuanced. The overall technical trend has shifted from bearish to mildly bearish, signalling a tentative easing of downward pressure but no clear reversal yet.

The Moving Average Convergence Divergence (MACD) indicator remains bearish on the weekly timeframe, indicating that momentum is still tilted towards sellers. The monthly MACD reading is inconclusive, suggesting a lack of strong directional conviction over the longer term.

Relative Strength Index (RSI) readings on both weekly and monthly charts show no clear signal, hovering in neutral zones. This absence of oversold or overbought conditions implies that the stock is neither deeply undervalued nor overextended, leaving room for either a rebound or further decline depending on market catalysts.

Bollinger Bands reinforce the bearish stance, with both weekly and monthly indicators signalling downward pressure. The stock price remains near the lower band, often interpreted as a sign of weakness but also a potential precursor to a bounce if buying interest emerges.

Daily moving averages continue to be bearish, with the stock trading below key averages, confirming the prevailing downtrend in the short term.

Volume and Trend Confirmation

On the volume front, the On-Balance Volume (OBV) indicator presents a more optimistic view. Weekly OBV is mildly bullish, and monthly OBV is bullish, suggesting that despite price declines, accumulation by investors may be occurring. This divergence between price and volume can sometimes precede a trend reversal if sustained.

The Know Sure Thing (KST) oscillator remains bearish on the weekly chart, with no clear monthly signal, indicating that momentum remains subdued.

Dow Theory assessments provide a mixed signal: weekly readings are mildly bullish, hinting at some short-term optimism, while monthly readings remain mildly bearish, reflecting longer-term caution.

Mojo Score and Grade Implications

Concord Biotech’s Mojo Score currently stands at 34.0, reflecting a Sell rating, which was downgraded from Strong Sell on 17 Feb 2026. This downgrade signals a slight improvement in the company’s outlook but still indicates caution for investors. The Market Cap Grade is 3, suggesting a mid-tier market capitalisation relative to peers in the Pharmaceuticals & Biotechnology sector.

The downgrade from Strong Sell to Sell may reflect the mildly bullish signals seen in volume and Dow Theory weekly readings, but the overall technical and price momentum remains weak. Investors should weigh these mixed signals carefully, especially given the stock’s significant underperformance relative to the Sensex over multiple timeframes.

Sector and Industry Context

Within the Pharmaceuticals & Biotechnology sector, Concord Biotech faces stiff competition and sector-specific headwinds. The sector has seen varied performance, with some companies benefiting from innovation and regulatory approvals, while others struggle with pricing pressures and supply chain disruptions. Concord’s technical indicators suggest it has yet to capitalise on any sector tailwinds, remaining in a corrective phase.

Given the stock’s current technical profile, investors may want to monitor key support levels near ₹1,100.00 and watch for confirmation of trend reversal signals such as a bullish MACD crossover or RSI moving above 50 on weekly charts.

Investor Takeaway and Outlook

Concord Biotech’s technical parameters reveal a stock caught in a challenging phase. While some weekly indicators hint at mild bullishness, the dominant trend remains bearish, particularly on monthly and daily timeframes. The stock’s significant underperformance relative to the Sensex over the past year and year-to-date periods emphasises the need for caution.

Investors should closely monitor technical signals such as MACD crossovers, RSI movements, and volume trends for signs of a sustained reversal. Until then, the Sell rating and Mojo Score of 34.0 suggest that the stock may continue to face downward pressure or sideways consolidation.

Given the mixed signals, a prudent approach would be to await clearer confirmation of trend improvement before increasing exposure. Meanwhile, exploring alternative investment opportunities within the Pharmaceuticals & Biotechnology sector or other sectors may be advisable for those seeking more robust technical and fundamental profiles.

Summary

In summary, Concord Biotech Ltd’s recent technical parameter changes reflect a complex interplay of bearish momentum and emerging mild bullish signals. The downgrade in Mojo Grade to Sell aligns with the stock’s ongoing struggles to regain upward momentum. While volume indicators and weekly Dow Theory readings offer some optimism, the prevailing technical landscape advises caution. Investors should remain vigilant for definitive trend reversals before committing significant capital.

Unlock special upgrade rates for a limited period. Start Saving Now →